- Researchers have identified a new radioactive substance called CB-2PA-NT as a promising candidate for a theranostics strategy, combining therapy and diagnostics.
- The substance, which targets neurotensin receptors found in various cancers, demonstrates high uptake and retention in tumors while maintaining a clear distinction from surrounding tissues.
- With regulatory approval pending, researchers hope to conduct human imaging studies using CB-2PA-NT in the near future, which could impact personalized medicine for cancer patients.
The University of North Carolina and the University of Wisconsin have collaborated on developing a new anti-cancer drug candidate, called CB-2PA-NT, that may have a wide application.
This research lays the groundwork for future studies to use CB-2PA-NT in human imaging, although, regulatory approval is still needed before these studies can commence.
New study findings, presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2023), position CB-2PA-NT as a promising candidate for an innovative
Finding the right treatment depends on the correct diagnosis. In the age of personalized medicine, where therapies can be customized according to a person’s specific biomarkers, an accurate diagnosis is even more essential.
This is particularly evident in the field of oncology, where the significance of obtaining a precise diagnosis is vital.
Theranostics presents a powerful strategy in the fight against cancer, combining two essential elements. It involves identifying cancer cells throughout the body and administering specialized radiation to eliminate them.
To pinpoint the cancer, positron emission tomography (PET) is employed, followed by the administration of medication to eradicate it. The remarkable precision of theranostics significantly lowers the likelihood of harming neighboring healthy tissues.
By specifically targeting neurotensin receptors (NTSRs) found in various types of cancer, CB-2PA-NT…
Read the full article here